Silk Road Medical Inc. provided earnings guidance for the quarter ended September 30, 2022. For the period, the company preliminary estimated revenue was $37.4 million, as compared to $24.7 million for the three months ended September 30, 2021, an increase of $12.7 million or 51% compared to three months ended September 30, 2021. The company's estimated net loss was between $10.2 million and $10.6 million, as compared to $13.9 million for the three months ended September 30, 2021, a decrease of between $3.3 million and $3.7 million or between 24% and 27%, compared to the three months ended September 30, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.74 USD | +5.84% | -0.87% | +77.18% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.18% | 858M | |
-7.16% | 178B | |
-1.23% | 107B | |
-4.86% | 67.04B | |
-4.28% | 47.23B | |
+10.32% | 44.62B | |
+9.25% | 42.5B | |
+15.97% | 25.22B | |
-5.88% | 24.14B | |
-5.38% | 23.69B |
- Stock Market
- Equities
- SILK Stock
- News Silk Road Medical, Inc
- Silk Road Medical, Inc Provides Earnings Guidance for the Quarter Ended September 30, 2022